Nicholas Grund's most recent trade in Akebia Therapeutics Inc. was a trade of 292,300 Stock Option (Right to buy) done . Disclosure was reported to the exchange on Jan. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 292,300 | 292,300 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 194,900 | 498,200 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Nicholas Grund | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 2.10 per share. | 31 Jan 2025 | 55,621 | 442,579 (0%) | 0% | 2.1 | 116,804 | Common Stock |
| Akebia Therapeutics Inc. | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 454,950 | 454,950 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Nicholas Grund | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 303,300 | 303,300 (0%) | 0% | 0 | Common Stock |